In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Industry session of the month

 

Dyslipidaemia and type 2 diabetes - the two ugly sisters
Session

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2021

Topic : Lipids

  • Session type : Symposium
  • Date : 17 April 2021
  • Time : 16:40 - 17:25

This content is currently on FREE ACCESS

 

5 presentations in this session

Dyslipidaemia in type 2 diabetes: scope of the problem.

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2021

  • Session : Dyslipidaemia and type 2 diabetes - the two ugly sisters
  • Speaker : F Mach (Geneva,CH)

When statins are not enough: emerging pharmacological tools.

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2021

  • Session : Dyslipidaemia and type 2 diabetes - the two ugly sisters
  • Speaker : U Landmesser (Berlin,DE)

SGLT2 inhibitors: beyond their glucose-lowering effects.

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2021

  • Session : Dyslipidaemia and type 2 diabetes - the two ugly sisters
  • Speaker : A Avogaro (Padua,IT)

Triglyceride-rich lipoproteins: is weight loss the solution?

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2021

  • Session : Dyslipidaemia and type 2 diabetes - the two ugly sisters
  • Speaker : J Armitage (Oxford,GB)

Dyslipidaemia and type 2 diabetes - the two ugly sisters - discussion.

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2021

  • Session : Dyslipidaemia and type 2 diabetes - the two ugly sisters

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are